Anna Wijatyk

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

Genovefa A. Papanicolaou, Fernanda P. Silveira, Amelia Langston et al. · Clinical Infectious Diseases · 2018 · 219 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

Johan Maertens, Catherine Cordonnier, Péter Jaksch et al. · New England Journal of Medicine · 2019 · 181 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Michael Beck, Derralynn Hughes, Christoph Kampmann et al. · Molecular Genetics and Metabolism Reports · 2015 · 128 citations · Full text

Life Sciences, Biochemistry, Enzymology +5

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

Raphael Schiffmann, Gregory M. Pastores, Yeong‐Hau H. Lien et al. · Orphanet Journal of Rare Diseases · 2014 · 37 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +12

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Lubor Goláň, Özlem Göker-Alpan, Myrl Holida et al. · Drug Design Development and Therapy · 2015 · 22 citations · Full text

Medicine, Cardiology, Pharmacotherapy +11